Formulary
Respiratory syncytial virus (RSV) vaccine: Indications, Dosing, Side Effects and Interactions
For respiratory syncytial virus (RSV) vaccine Abrysvo contains recombinant prefusion F proteins from both respiratory syncytial virus subtypes, A and B,...
MedNext Academy | 3 min read
Respiratory syncytial virus (RSV) vaccine: Indications, Dosing, Side Effects and Interactions
For respiratory syncytial virus (RSV) vaccine Abrysvo contains recombinant prefusion F proteins from both respiratory syncytial virus subtypes, A and B,...
Drug action
For respiratory syncytial virus (RSV) vaccine Abrysvo contains recombinant prefusion F proteins from both respiratory syncytial virus subtypes, A and B, which elicit an immune response against the virus; infants gain protection via transplacental transfer of neutralising antibodies. Arexvy contains recombinant prefusion F protein with an adjuvant, to elicit an immune response against respiratory syncytial virus.
Indications and dose
**Immunisation against respiratory syncytial virus [as part of the national immunisation programme]**
- **Adult** (By Intramuscular Injection): 75-79 years 0.5 mL for 1 dose.
**Immunisation against respiratory syncytial virus [not part of the national immunisation programme]**
- **Adult** (By Intramuscular Injection): 60 years and over 0.5 mL for 1 dose.
**Immunisation against respiratory syncytial virus [in patients at increased risk; not part of the national immunisation programme]**
- **Adult** (By Intramuscular Injection): 50-59 years 0.5 mL for 1 dose.
**Passive immunisation against respiratory syncytial virus [pregnant females from week 28 gestation; as part of the national immunisation programme] for Abrysvo**
- **Females of childbearing potential** (By intramuscular injection): 0.5 mL for 1 dose.
Cautions
For all vaccines, general Acute illness; minor illnesses Cautions, further information Illness UKHSA advises vaccination may be postponed if the individual is suffering from an acute illness; however, it is not necessary to postpone immunisation in patients with minor illnesses without fever or systemic upset. Predisposition to neurological problems UKHSA advises: when there is a personal or family history of febrile convulsions, there is an increased risk of these occurring during fever from any cause including immunisation, but this is not a contra-indication to immunisation. In children who have had a seizure associated with fever without neurological deterioration, immunisation is recommended ; advice on the management of fever should be given before immunisation. When a child has had a convulsion not associated with fever, and the neurological condition is not deteriorating, immunisation is recommended ; children with stable neurological disorders (e.g. spina bifida, congenital brain abnormality, and peri-natal hypoxic-ischaemic encephalopathy) should be immunised according to the recommended schedule; when there is a still evolving neurological problem , including poorly controlled epilepsy, immunisation should be deferred and the child referred to a specialist. Immunisation is recommended if a cause for the neurological disorder is identified. If a cause is not identified, immunisation should be deferred until the condition is stable. Impaired immune response and drugs affecting immune response Immune response to vaccines may be reduced in immunosuppressed patients, UKHSA advises consider seeking specialist advice.
Side effects
For all vaccines, general Common or very common Abdominal pain; appetite decreased; arthralgia; diarrhoea; dizziness; fatigue; fever; headache; lymphadenopathy; malaise; myalgia; nausea; skin reactions; vomiting Uncommon Hypersensitivity Side-effects For respiratory syncytial virus (RSV) vaccine Common or very common Chills; vaccination reactions Uncommon Pain Rare or very rare Guillain-Barre syndrome
Pregnancy
For Arexvy Avoid (no information available). M
Breast feeding
For respiratory syncytial virus (RSV) vaccine Specialist sources indicate not known to be harmful.
Medicinal forms
Solution,Injection
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Respiratory syncytial virus (RSV) vaccine in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

